Ticker Hub
TRVI — AI Analysis & Sentiment
4 recent AI-generated analyses for TRVI. Sentiment and confidence insights updated continuously.
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Trevi Therapeutics' successful $173 million capital raise provides crucial funding for its Haduvio pipeline, significantly de-risking near-term ope...
Apr 20, 2026Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics successfully priced a $150 million stock offering, securing vital funding for its operations. This significantly de-risks the co...
Apr 17, 2026Trevi Therapeutics Announces Proposed Public Offering of Common Stock
Trevi Therapeutics' public offering provides essential capital for its Haduvio clinical trials, significantly extending its operational runway. Thi...
Apr 16, 2026Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Trevi Therapeutics received FDA alignment for its pivotal Phase 3 program for Haduvio, significantly de-risking its lead candidate. This, combined ...
Mar 17, 2026